What is the mechanism of action of the drug?
Aducanumab (Aduhelm) is a monoclonal antibody that was developed in a lab to bind to the amyloid molecule that causes plaques in Alzheimer's patient's brains. The plaques, according to most researchers, form first and harm brain cells, prompting tau tangles to form inside them, eventually killing the cells. When aducanumab binds to the plaque, your body's immune system attacks it, mistaking it for a foreign invader and removing it. The goal is that after the plaques are removed, the brain cells will stop dying, and thinking, memory, function, and behavior will improve.